Skip to main content
IMS Events Main banner
Back

    Steven P. Treon, MD, PhD, FACP, FRCP (he/him/his)

    Professor of Medicine, Harvard Medical School
    Dana-Farber Cancer Institute, Bing Center for Waldenstroms macroglobulinemia
    BOSTON, Massachusetts, United States

    Steve Treon is the Director of the Bing Center for Waldenstrom’s Macroglobulinemia (WM) at the Dana Farber Cancer Institute (DFCI), a Professor of Medicine at Harvard Medical School, and Chair of the WM Clinical Trials Group. His laboratory first identified highly recurring activating mutations in MYD88 and CXCR4 using whole genome sequencing. Dr. Treon’s laboratory also identified that Bruton’s tyrosine kinase (BTK) was a downstream target of mutated MYD88, and enabled a clinical trial with the BTK inhibitor ibrutinib that resulted in the first-ever approval of a drug by the U.S. FDA and the European Medicines Agency for WM. Dr. Treon also made major contributions to the investigation and advancement of many novel agents used to treat WM including monoclonal antibodies, nucleoside analogues, bendamustine, proteasome inhibitors, and BTK inhibitors.

    Dr. Treon has delivered numerous scientific and clinical lectures worldwide, and his scientific work has earned “Best of ASH” designations. He has published extensively on topics in WM and myeloma with over 280 peer-reviewed original reports, authoritative reviews, editorials, and chapters included in high-impact journals and textbooks. He has been the principal organizer of the International Workshops on WM since 2002. Dr. Treon is an active member of the Workshop Committee for the International Myeloma Society (IMS), and was the Chair of the 17th International Myeloma Workshop. His scientific and clinical research contributions in WM have been acknowledged by many awards; Robert A. Kyle Award, the J.G. Waldenstrom Lifetime Achievement Award, the L. Strauss Leukemia Foundation Outstanding Cancer Investigator Award, designation as “America’s Top Doctor” by U.S. News and World Report, the prestigious “One Hundred Award” from the Massachusetts General Hospital for Outstanding Cancer Research, the Bruce Waterfall Memorial Award from Weill Cornell Medical School, the Medical Oncology Discoverer Award for seminal work in Medical Oncology by the DFCI.

    Disclosure information not submitted.

    Presentation(s):